Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...

Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...

Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer – First Pivotal ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy). Data from the phase III ASCENT-03 ...

Patients who took Trodelvy-Keytruda went a median 11.2 months without progression, versus 7.8 months for chemo-Keytruda, according to results from the phase 3 Ascent-04 trial to be presented at ...

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...